N. Tassopoulos

发表

A case‐control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma

D. Trichopoulos, N. Mueller, S. Stuver, 1995, International journal of cancer.

Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection

A. Hatzakis, G. Touloumi, V. Sypsa, 2004, Journal of viral hepatitis.

Double infections with hepatitis A and B viruses.

R. Purcell, J. Gerin, R. Engle, 2008, Liver.

Differential diagnosis of acute HBsAg positive hepatitis using IgM anti-HBc by a rapid, fully automated microparticle enzyme immunoassay.

A. Hatzakis, E. Tzala, M. Koutelou, 1997, Journal of hepatology.

A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.

J. Bruix, J. Llovet, P. Ruff, 2001, European journal of cancer.

Fecal excretion of Greek strains of hepatitis A virus in patients with hepatitis A and in experimentally infected chimpanzees.

R. Purcell, J. Ticehurst, G. Papaevangelou, 1986, The Journal of infectious diseases.

Detection of hepatitis B virus DNA in asymptomatic hepatitis B surface antigen carriers: relation to sexual transmission.

R. Purcell, J. Ticehurst, G. Papaevangelou, 1987, American journal of epidemiology.

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.

M. Buti, R. Goldin, J. Heathcote, 1999, Hepatology.

Factors associated with severity and disease progression in chronic hepatitis C.

A. Hatzakis, G. Touloumi, V. Sypsa, 1998, Hepato-gastroenterology.

Patterns of progression

N. Tassopoulos, 1996, Digestive Diseases and Sciences.

Clinical and Laboratory Features of Acute Community-acquired Non-A, Non-B, Non-C Hepatitis

D. Trichopoulos, V. Miriagou, A. Hatzakis, 1994 .

Role of hepatitis C virus in acute non-A, non-B hepatitis in Greece: a 5-year prospective study.

V. Miriagou, A. Hatzakis, I. Delladetsima, 1992, Gastroenterology.

Serological markers of hepatitis B virus and hepatitis D virus infections in Greek adults with primary hepatocellular carcinoma

R. Purcell, G. Theodoropoulos, R. Engle, 2005, Infection.

Detection of hepatitis A virus by extraction of viral RNA and molecular hybridization

R. Purcell, J. Ticehurst, H. Popper, 1987, Journal of clinical microbiology.

Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B

P. Marcellin, J. Ma, Z. Goodman, 2005 .

Clinicopathological features and natural history of acute sporadic non‐(A‐E) hepatitis

A. Hatzakis, I. Delladetsima, G. Papatheodoridis, 2008, Journal of gastroenterology and hepatology.

Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis

H. Thomas, Roger Williams, W. Carman, 1991, Hepatology.

IgM antibody to hepatitis B core antigen: a marker of infectivity.

R. Purcell, G. Papaevangelou, A. Roumeliotou, 1985, The New England journal of medicine.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

George Kitis, Katyna Borroto-Esoda, P. Marcellin, 2006, Gastroenterology.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

M. Wulfsohn, P. Marcellin, Z. Goodman, 2003, The New England journal of medicine.

Novel hepatitis E virus (HEV) isolates from Europe: Evidence for additional genotypes of HEV

A. Zanetti, S. Desai, I. Mushahwar, 1999, Journal of medical virology.

241 Long-term (96 weeks) adefovir dipivoxil in HBEAG negative chronic hepatitis results in significant virological, biochemical and histological improvement

M. Wulfsohn, P. Marcellin, S. Lim, 2003 .

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Graeme Currie, George Kitis, P. Marcellin, 2005, The New England journal of medicine.

Famciclovir treatment of anti-HBE+ chronic hepatitis B: Results of a randomized, placebo-controlled study

C. Trépo, F. Bonino, R. Saltzman, 2000 .

Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B

P. Marcellin, M. Tong, S. Arterburn, 2007, Alimentary pharmacology & therapeutics.

46 Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES)

P. Marcellin, S. Lim, M. Rizzetto, 2004 .

Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B

M. Wulfsohn, P. Marcellin, S. Lim, 2003 .

Development and assessment of a novel real-time PCR assay for quantitation of HBV DNA.

D. Paraskevis, A. Hatzakis, N. Tassopoulos, 2002, Journal of virological methods.

P.102 Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy

P. Marcellin, Z. Goodman, S. Lim, 2006 .

Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults.

R. Purcell, J. Gerin, G. Papaevangelou, 1987, Gastroenterology.

A viral kinetic study using pegylated interferon alpha 2b and lamivudine in naive patients with HBeAg(−)/I-BV-DNA(+) chronic hepatitis B: preliminary results

A. Hatzakis, K. Mimidis, D. Paraskevis, 2002 .

Significance of IgM antibody to hepatitis B core antigen in a Greek population with chronic hepatitis B virus infection.

R. Purcell, J. Ticehurst, J. Gerin, 2008, Liver.

Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis.

William M. Lee, M. Manns, A. E. Yeo, 2003, The Journal of infectious diseases.

Diagnostic significance of IgM antibody to hepatitis delta virus in fulminant hepatitis B

M. Rizzetto, S. Macagno, M. Koutelou, 1990, Journal of medical virology.

Pre-S2 and its antibody in fulminant type B hepatitis.

A. Budkowska, S. Hadziyannis, N. Tassopoulos, 1989, JAMA.

Etiology of Fulminant Viral Hepatitis in Greece

G. Papaevangelou, N. Tassopoulos, A. Roumeliotou‐Karayannis, 1984, Hepatology.

1159 Lack of ethnic differences in response to adefovir dipivoxil therapy in HBEAG+ and HBEAG- patients with chronic hepatitis B

P. Marcellin, S. Lim, Ting Chang, 2003 .

CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

P. Marcellin, Z. Goodman, S. Lim, 2006 .

Quantitative detection of hepatitis B virus DNA in sera from patients with acute hepatitis B

M. Koutelou, N. Tassopoulos, M. Kuhns, 1993, Digestive Diseases and Sciences.

Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis.

A. Hatzakis, I. Delladetsima, M. Koutelou, 1993, Gut.

Fulminant Hepatitis in Asymptomatic Hepatitis B Surface Antigen Carriers in Greece

R. Purcell, J. Ticehurst, R. Engle, 1986, Journal of medical virology.

Search for hepatitis B virus DNA in sera from patients with acute type B or non-A, non-B hepatitis.

R. Purcell, J. Ticehurst, G. Papaevangelou, 1986, Journal of hepatology.

HLA-associated non-responsiveness to hepatitis B vaccine.

M. Spyropoulou, M. Papanicolaou, N. Tassopoulos, 1990, Tissue antigens.

Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.

Christos G Gogos, G. Touloumi, G. Papatheodoridis, 2014, Hippokratia.

Efficacy of different doses of 12-month Interferon alfa therapy in patients with HBeAg negative chronic hepatitis B: A randomized trial

A. Hatzakis, I. Delladetsima, G. Papatheodoridis, 2007 .

Diagnostic value of anti‐HBc IgM in high hbv prevalence areas

P. Stathopoulou, G. Papaevangelou, N. Tassopoulos, 1984, Journal of medical virology.

A survey of bloodborne viruses and associated risk behaviours in Greek prisons.

C. Stefanis, A. Hatzakis, G. Touloumi, 1998, Addiction.

Serologic markers of hepatitis B virus (HBV) and hepatitis D virus infection in carriers of hepatitis B surface antigen who are frequently exposed to HBV.

R. Purcell, R. Engle, G. Papaevangelou, 1986, Hepato-gastroenterology.

Natura1 History of Acute Hepatitis B Surface Antigen-Positive Hepatitis in

R. Purcell, J. Gerin, G. Papaevangelou, 1987 .

Correlation of hepatitis B surface antigen clearance with the route of hepatitis B virus infection

G. Papaevangelou, N. Tassopoulos, 1990, Journal of gastroenterology and hepatology.

Acute sporadic non‐A, non‐B hepatitis in Greece

N. Tassopoulos, Michael Alikiotis, Fragiscos Limotirakis, 1988, Journal of medical virology.

Significance of IgM anti-HCV core level in chronic hepatitis C.

A. Hatzakis, V. Sypsa, G. Papatheodoridis, 1997, Journal of hepatology.

Mixed cryoglobulinemia and HCV

N. Tassopoulos, Papageorgiou N. Johanna, 2007 .

19S and 7-8S forms of IgM antibody to hepatitis B core antigen in acute icteric hepatitis superimposed on hepatitis B surface antigen carriage

R. Purcell, M. Sjogren, N. Tassopoulos, 1990, Infection.

Prevalence of antibodies to hepatitis C virus in Greek patients with chronic liver disease.

A. Hatzakis, I. Delladetsima, M. Koutelou, 1994, Journal of Hepatology.

An epidemic of hepatitis A in an institution for young children.

R. Purcell, J. Ticehurst, G. Papaevangelou, 1987, American journal of epidemiology.

Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments.

A. Hatzakis, G. Touloumi, V. Sypsa, 2004, Journal of viral hepatitis.

Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype‐specific incidence and molecular characterization of genotype 4 isolates

G. Magiorkinis, A. Hatzakis, G. Kitis, 2006, Journal of viral hepatitis.

Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis

H. Thomas, Roger Williams, W. Carman, 1991, Hepatology.

Hepatitis C virus 1b is the dominant genotype in HCV‐related carcinogenesis: A case‐control study

D. Trichopoulos, A. Hatzakis, G. Karvountzis, 1996, International journal of cancer.

Expression of a hepatitis E virus (HEV)-trpE fusion protein containing epitopes recognized by antibodies in sera from human cases and experimentally infected primates

D. Bradley, G. Reyes, M. Purdy, 2005, Archives of Virology.

Fatal reactivation of chronic hepatitis B.

N. Tassopoulos, 1987, Journal of the American Medical Association (JAMA).

Case report: Role of hepatitis E virus in the etiology of community‐acquired non‐A, non‐B hepatitis in greece

D. Trichopoulos, A. Hatzakis, I. Delladetsima, 1994, Journal of medical virology.

Prevalence patterns and genotypes of GB Virus C/hepatitis G virus among imprisoned intravenous drug users

A. Hatzakis, C. Anastassopoulou, D. Paraskevis, 1998, Journal of medical virology.

Terbinafine-induced cholestatic liver disease.

G. Lazaros, G. Papatheodoridis, N. Tassopoulos, 1996, Journal of hepatology.

Quantitative detection of hepatitis B virus DNA in sera from patients with acute hepatitis B

M. Koutelou, N. Tassopoulos, M. Kuhns, 1993, Digestive Diseases and Sciences.

Reactivation of chronic hepatitis B as acute viral hepatitis.

R. Purcell, G. Papaevangelou, N. Tassopoulos, 1985, Annals of internal medicine.

Serological profile of “healthy” hepatitis B surface antigen carriers and heterosexual transmission of hepatitis B virus

N. Tassopoulos, M. Paraloglou-Ioannides, 2005, Infection.